• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    6/30/25 4:26:17 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRNX alert in real time by email
    8-K
    false000165824700016582472025-06-302025-06-30

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 30, 2025

     

     

    Crinetics Pharmaceuticals, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38583

    26-3744114

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    6055 Lusk Boulevard

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 450-6464

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    CRNX

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 7.01 Regulation FD Disclosure.

    On June 30, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release announcing eight abstracts from its novel clinical development programs to be presented at the Endocrine Society’s Annual Meeting, ENDO 2025, which is taking place from July 12-15, 2025 in San Francisco, California. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    The information contained in this Item 7.01, including in Exhibit 99.1 hereto, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Forward-Looking Statements

    This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical facts contained in this Current Report on Form 8-K are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the plans and timelines for the commercial launch of PALSONIFY if approved; the potential clinical benefits of Crinetics’ TSHR antagonist, CRN12755, in patients across multiple indications, and the anticipated timing of clinical trials, registration applications or the therapeutic potential for Crinetics’ development candidates. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, initial or topline data that Crinetics reports may change following completion or a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with Crinetics’ interpretation of such results; geopolitical events may disrupt Crinetics’ business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; the success of Crinetics’ clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics’ drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company’s periodic filings with the Securities and Exchange Commission (“SEC”). The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

    Description

    99.1

    Press Release dated June 30, 2025.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    Crinetics Pharmaceuticals, Inc.

     

     

     

     

    Date:

    June 30, 2025

    By:

    /s/ R. Scott Struthers, Ph.D.

     

     

     

    R. Scott Struthers, Ph.D.
    President and Chief Executive Officer
    (Principal Executive Officer)

     


    Get the next $CRNX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRNX

    DatePrice TargetRatingAnalyst
    3/25/2025$60.00Buy
    Stifel
    2/11/2025Buy
    TD Cowen
    2/4/2025Peer Perform
    Wolfe Research
    1/22/2025$55.00Hold → Buy
    Jefferies
    3/6/2024$68.00Buy
    Citigroup
    1/16/2024$50.00Overweight
    Morgan Stanley
    12/21/2023$35.00Hold
    Jefferies
    11/20/2023$35.00Overweight
    JP Morgan
    More analyst ratings

    $CRNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Crinetics Pharmaceuticals with a new price target

      Stifel initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $60.00

      3/25/25 8:26:55 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Crinetics Pharmaceuticals

      TD Cowen initiated coverage of Crinetics Pharmaceuticals with a rating of Buy

      2/11/25 7:03:38 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Crinetics Pharmaceuticals

      Wolfe Research initiated coverage of Crinetics Pharmaceuticals with a rating of Peer Perform

      2/4/25 7:01:38 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

      SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti

      2/24/25 8:30:00 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

      SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company's commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company's deep, innovative pipeline of candidates. "Isabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy," said Scott Struthers, Ph.D

      12/16/24 8:00:00 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

      SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs. "Dr. Cuddihy's wealth of knowledge and experience both as a practicing physician in endocrinology and working within the pharmaceutical industry is an invaluable addition to our talented scientific leadership team," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "As we forg

      5/30/24 4:05:00 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

      SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

      11/14/24 7:55:29 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

      SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

      11/14/24 5:46:54 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Crinetics Pharmaceuticals Inc.

      SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

      11/14/24 1:22:38 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Betz Stephen F. exercised 88,170 shares at a strike of $3.30 and sold $3,141,877 worth of shares (97,483 units at $32.23), decreasing direct ownership by 9% to 99,713 units (SEC Form 4)

      4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

      6/16/25 4:48:09 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deardorf Caren was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

      4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

      6/13/25 4:30:20 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Okey Stephanie was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

      4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

      6/13/25 4:30:20 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

      SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that it will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00 AM to 12:00 PM ET. The event will provide an update including data on Crinetics' early-stage pipeline assets, next steps, and portfolio strategy to drive long-term value. Key topics will include: NETs and beyond – NDC platform with CRN09682Graves' disease and thyroid eye disease (TED) - TSH antagonistAutosomal polycystic kidney disease (ADPKD) - SST3 agonist A live question-and-answer session will follow the formal presentations. To register, click here. About Crinetics Pharmaceut

      6/16/25 8:00:00 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit ("RSU") awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4)

      6/10/25 4:29:30 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

      SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY. Jefferies Global Healthcare Conference 2025Company presentation: Thursday, June 5, 2025 at 12:50 p.m. Eastern TimeWebcast link: HERE The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at www.crinetics.com/events. If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Ph

      5/23/25 8:00:00 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    SEC Filings

    See more
    • Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

      6/30/25 4:26:17 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

      6/26/25 4:16:14 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

      6/12/25 4:27:42 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    Financials

    Live finance-specific insights

    See more
    • Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date   CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal Hyperplasia to Initiate with Uncompromising Primary Endpoint to Normalize Androstenedione Levels with Physiologic Glucocorticoid Replacement R&D Day Scheduled for June 26 to Share Early-Stage Pipeline Strategy and Data $1.3B in Cash, Cash Equivalents, and Investment Securities as of March 31, 2025 Anticipated to Provide Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Crin

      5/8/25 4:05:00 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

      SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 8 @ 4:30 p.m. ET Domestic:1-833-470-1428International:1-404-975-4839Conference ID:CRNXQ1 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended

      4/11/25 8:00:00 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

      SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 27 @ 4:30 p.m. ET Domestic:         1-800-267-6316International:    1-203-518-9783Conference ID:  CRNXQ4 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely

      2/6/25 4:35:20 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care